<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-2448</journal-id>
<journal-title><![CDATA[Acta Medica Colombiana]]></journal-title>
<abbrev-journal-title><![CDATA[Acta Med Colomb]]></abbrev-journal-title>
<issn>0120-2448</issn>
<publisher>
<publisher-name><![CDATA[Asociacion Colombiana de Medicina Interna]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-24482022000200032</article-id>
<article-id pub-id-type="doi">10.36104/amc.2022.2216</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Pleural involvement in differentiated thyroid cancer]]></article-title>
<article-title xml:lang="es"><![CDATA[Compromiso pleural en cáncer diferenciado de tiroides]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[ROJAS-MELO]]></surname>
<given-names><![CDATA[LEONARDO]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[QUIJANO-NARANJO]]></surname>
<given-names><![CDATA[JOSSIE ESTEBAN]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[SALGADO-SÁNCHEZ]]></surname>
<given-names><![CDATA[JUAN CAMILO]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[SANKÓ-POSADA]]></surname>
<given-names><![CDATA[ANDREY ALEXANDROVICH]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[MOLINA-PLMIENTA]]></surname>
<given-names><![CDATA[LUISANA]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario San Ignacio  ]]></institution>
<addr-line><![CDATA[Bogotá. D.C. ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Pontificia Universidad Javeriana  ]]></institution>
<addr-line><![CDATA[Bogotá. D.C. ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Pontificia Universidad Javeriana  ]]></institution>
<addr-line><![CDATA[Bogotá. D.C. ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Universitario San Ignacio  ]]></institution>
<addr-line><![CDATA[Bogotá. D.C. ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<volume>47</volume>
<numero>2</numero>
<fpage>32</fpage>
<lpage>34</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-24482022000200032&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-24482022000200032&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-24482022000200032&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Thyroid cancer is the most common endocrine cancer. It generally has a good prognosis, with a 10-year survival rate of over 90%. Pleural metastasis is uncommon. We present two cases of papillary thyroid cancer with pleural metastases. (Acta Med Colomb 2022; 47. DOI:https://doi.org/10.36104/amc.2022.2216).]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El cáncer de tiroides es la neoplasia endocrinológica más común. Suele presentar un buen pro nóstico con una sobrevida a 10 años mayor al 90%. El compromiso metastásico pleural es poco frecuente. Presentamos dos casos de cáncer papilar de tiroides con compromiso pleural metastásico. (Acta Med Colomb 2022; 47. DOI:https://doi.org/10.36104/amc.2022.2216).]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[thyroid cancer]]></kwd>
<kwd lng="en"><![CDATA[malignant pleural effusion]]></kwd>
<kwd lng="es"><![CDATA[cáncer de tiroides]]></kwd>
<kwd lng="es"><![CDATA[derrame pleural maligno.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<collab>Surveillance Epidemiology and End Results program (SEER).</collab>
<article-title xml:lang=""><![CDATA[Cancer Stat Facts: Thyroid Cancer.]]></article-title>
<source><![CDATA[Natl cancer Inst]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>International Agency for Research on Cancer</collab>
<source><![CDATA[Global Cancer Observatory (GLOBOCAN).]]></source>
<year></year>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vassilopoulou-Sellin]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sneige]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pleural Effusion in Patients With Differentiated Papillary Thyroid Cancer.]]></article-title>
<source><![CDATA[South Med J.]]></source>
<year>1994</year>
<volume>87</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1111-1116.</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tamura]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shiozawa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Satoh]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pleural fluid due to papillary thyroid cancer.]]></article-title>
<source><![CDATA[Oncol Lett]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Broome]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Gadre]]></surname>
<given-names><![CDATA[GB]]></given-names>
</name>
<name>
<surname><![CDATA[Fayazzadeh]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bena]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Nasr]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pleural effusion as a novel prognostic factor in metastatic thyroid carcinoma.]]></article-title>
<source><![CDATA[Endocr Connect.]]></source>
<year>2020</year>
<volume>9</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>812-23</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hyman]]></surname>
<given-names><![CDATA[MP.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Papillary and undifferentiated thyroid carcinoma presenting as a metastatic papillary serous effusion. A case report.]]></article-title>
<source><![CDATA[Acta Cytol.]]></source>
<year>1979</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jeon]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Yim]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[EY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Four Cases of Malignant Pleural Effusion in Patients with Papillary Thyroid Carcinoma.]]></article-title>
<source><![CDATA[Endocrinol Metab]]></source>
<year>2011</year>
<volume>26</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>330</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vernon]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
<name>
<surname><![CDATA[Sheeler]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[Biscotti C]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Stoller]]></surname>
<given-names><![CDATA[JK.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pleural Effusion Resulting from Metastatic Papillary Carcinoma of the Thyroid]]></article-title>
<source><![CDATA[Chest]]></source>
<year>1992</year>
<volume>101</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1448-50</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abe]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shimizu]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anaplastic transformation of papillary thyroid carcinoma in multiple lung metastases presenting with a malignant pleural effusion: a case report.]]></article-title>
<source><![CDATA[J Med Case Rep.]]></source>
<year>2014</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>460</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lew]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pang]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Roh]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Jing]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cytologic Features and Immunocyto-chemical Profiles of Malignant Effusions with Metastatic Papillaiy Thyroid Carcinoma: A Case Series from a Single Institution]]></article-title>
<source><![CDATA[Acta Cytol]]></source>
<year>2015</year>
<volume>59</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>412-7</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vyas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Harigopal]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metastatic thyroid carcinoma presenting as malignant pleural effusion: A cytologic review of 5 cases]]></article-title>
<source><![CDATA[Diagn Cytopathol]]></source>
<year>2016</year>
<volume>44</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1085-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenstengel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Millward]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[YG.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A distinctive colour associated with high iodine content in malignant pleural effusion from metastatic papillary thyroid cancer: a case report]]></article-title>
<source><![CDATA[J Med Case Rep.]]></source>
<year>2013</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>147</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schlumberger]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tahara]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wirth]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer.]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>372</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>621-30</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brose]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Nutting]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Jarzab]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2014</year>
<volume>384</volume>
<numero>9940</numero>
<issue>9940</issue>
<page-range>319-28</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ruan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Notable Decrease of Malignant Pleural Effusion After Treatment with Sorafenib in Radioiodine-Refractory Follicular Thyroid Carcinoma]]></article-title>
<source><![CDATA[Thyroid]]></source>
<year>2014</year>
<volume>24</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1179-83</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Uchida]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yamaguchi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Nagamine]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rapid pleural effusion after discontinuation of lenvatinib in a patient with pleural metastasis from thyroid cancer.]]></article-title>
<source><![CDATA[Endocrinol Diabetes Metab Case Reports]]></source>
<year>2019</year>
<volume>2019</volume>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
